Skye Bioscience, Inc. announce the appointment of Dr. Annalisa Jenkins, MBBS, FRCP, to the Company?s Board of Directors. Dr. Jenkins? esteemed career spans more than 25 years in the global pharmaceutical, biotechnology and life science industry.

She has broad experience in building and leading teams and developing strategies that have resulted in the advancement of new products across multiple disease areas from discovery through to clinical development, regulatory approval and commercialization worldwide. Dr. Jenkins currently provides board level and consulting services to organizations across the life science and healthcare industry. She previously served as President and CEO of Plaquetec Therapeutics and of Dimension Therapeutics, leading efforts to develop novel approaches in coronary vascular and rare diseases that included a significant worldwide partnership for a gene therapy approach to hemophilia A with Bayer Pharmaceuticals.

Prior to these roles, Dr. Jenkins held senior leadership roles at Merck Serono Pharmaceuticals as Global Head of Research and Development and at Bristol-Myers Squibb as Senior Vice President Global Medical. Dr. Jenkins sits on a number of boards across the public and private sectors and as a trustee of nonprofit organizations globally, including AVROBIO, COMPASS Pathways, MEREO Biopharmaceuticals, AFFIMED, The British Heart Foundation, The King?s Fund, Cancer Research Horizons, Genomics England and Faster Cures at the Milken Institute. As a pharmaceutical thought leader, Dr. Jenkins routinely contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.

Dr. Jenkins was commissioned by the British Royal Navy as a Surgeon Sub Lieutenant prior to graduating in medicine from St. Bartholomew?s Hospital in the U.K. Dr. Jenkins served as a medical officer in the British Royal Navy for nine years, achieving the rank of Surgeon Lieutenant Commander. On February 29, 2024, Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.

Dr. Dalesandro will also resign as a member of the Nominating and Corporate Governance Committee of the Board, the Audit Committee of the Board and the Compensation Committee of the Board, effective August 1, 2024. Dr. Dalesandro?s decision to resign from the Board is not as a result of any disagreement with the Company concerning any matter relating to its operations, policies or practices.